TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of YH25448 in Patients With EGFR Mutation Positive Advanced NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of NSCLC with single activating EGFR mutations.~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 3 months.~* At least one measurable extracranial lesion, not previously irradiated and not chosen biopsy during the study screening period.~* Prior to enrolling in the study, patients must have central confirmation of T790M+ mutation status from a sample taken after documented progression on the EGFR-TKIs therapy according to cohort.~Exclusion Criteria:~* Spinal cord compression.~* Brain metastases with symptomatic and/or requiring steroid for at least 2 weeks prior to start of study treatment.~* Known intracranial hemorrhage which is unrelated to tumor.~* Central Nervous System (CNS) complications that require urgent neurosurgical intervention (e.g. resection or shunt placement).~* Leptomeningeal metastasis prior to study treatment.~* Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.~* Any cardiovascular disease as followed.~  * History of symptomatic congestive heart failure (CHF) or serious cardiac arrhythmia requiring treatment~ * History of myocardial infarction or unstable angina within 6 months of the first dose of study treatment~ * Left ventricular ejection fraction (LVEF) \< 50%

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- YH25448 (Type: EXPERIMENTAL): * Dose Escalation Phase: Consists of 7 Cohorts~* Dose Expansion Phase: Consists of 5 Cohorts~* Dose Extension Phase: Consists of 2 Cohorts

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple myeloma based on standard diagnostic criteria or by the new International Myeloma Foundation 2003 Diagnostic Criteria~* Relapsed or relapsed and refractory disease after receiving between 1 and 3 prior regimens~* Negative serum or urine pregnancy test~* Age 18 years or older~* Karnofsky performance status of 60 or greater~Exclusion Criteria:~* Grade 2 or greater peripheral neuropathy within 14 days before enrollment~* Renal insufficiency (serum creatinine \> 2.5 mg/dL)~* Evidence of mucosal or internal bleeding and/or platelet refractory~* ANC \< 1000 cells/mm3~* Hemoglobin \< 8.0 g/dL~* AST or ALT greater than or equal to 2 x ULN~* Concomitant therapy medications that include corticosteroids~* Myocardial infarction within 6 months prior to enrollment or has NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities~* Clinically relevant active infection or serious co-morbid medical conditions~* Prior malignancy (within last 3 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical or breast cancer, in situ prostate cancer~* Pregnant or breast-feeding~* Serious medical or psychiatric illness likely to interfere with participation in this clinical study.~* Uncontrolled diabetes mellitus~* Hypersensitivity to acyclovir or similar anti-viral drug~* POEMS syndrome~* Known HIV infection~* Known active hepatitis B or C viral infection~* Known intolerance to steroid therapy~* Subjects with primary refractory disease, defined as progression during initial treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lenalidomide, dexamethasone, bortezomib combination (Type: EXPERIMENTAL): Participants took the study medication in the clinic on Cycle 1 day 1. Each treatment cycle lasted three weeks. They took the lenalidomide (capsules) every day for the first two weeks only (days 1-14). They took the dexamethasone (tablets) on Day 1, 2, 4, 5, 8, 9, 11 and 12 and came to the outpatient treatment center for intravenous bortezomib on Day 1, 4, 8 and 11. The third week of the cycle was a rest period and the participant did not take any study medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit MammaTyperTM

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Invasive breast cancer verified in a histological biopsy~* Age 65 or younger~* Estrogen receptor (ER), PgR and HER2 expression have been determined~* No distant metastases present (M0)~* The patient provides a written informed consent for study participation~* The estimated risk of breast cancer recurrence is high (25% or higher within the first 5 years from the date of the diagnosis, over \>35% within the first 10 years from the diagnosis)~Exclusion Criteria:~* Patients with breast cancer with a special histological type (mucinous, papillary, medullary, or tubular type of breast cancer) when no metastases are present in the ipsilateral axillary lymph nodes~* The WHO performance status is moderate/poor, Z \>1~* The peripheral blood leukocyte count is less than 3.0 x 109/L, the blood granulocyte count is less than 1.5 x 109/L, or the blood thrombocyte count is less than 120 x 109/L~* Any physical or mental disorder that is considered to prohibit administration of chemotherapy~* Cardiac failure; severe cardiac arrythmia requiring regular medication

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MammaTyper™ (Type: EXPERIMENTAL): MammaTyper™ kit will be used tio assess tumor material of patients enrolled into the FinHer trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- diagnosis of essential hypertension~Exclusion Criteria:~* pregnancy, breast-feeding, unwilling to use effective contraception (if female of child-bearing potential).~* development of any condition in the preceding trial that could be worsened by telmisartan 40mg/amlodipine 10mg (T40/A10) or telmisartan 80mg/amlodipine 10mg (T80/A10).~* discontinuation from the preceding trial.~* known or suspected secondary hypertension.~* mean seated systolic blood pressure (SBP) \>= 180 mmHg and/or mean seated diastolic blood pressure (DBP) \>= 120 mmHg at any visit.~* any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant.~* clinically relevant hyperkalaemia.~* uncorrected volume or sodium depletion.~* primary aldosteronism.~* hereditary fructose or lactose intolerance.~* symptomatic congestive heart failure.~* patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).~* any new drug or alcohol dependency since signing consent of the preceding trial.~* concurrent participation in another clinical trial or any investigational therapy since completing the preceding trial.~* hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve.~* known allergic hypersensitivity to any component of the formulations under investigation. \[Includes known hypersensitivity to telmisartan or other ARBs or amlodipine or other dihydropyridine calcium channel blockers (CCBs).\] non-compliance with study medication (defined as \<80% or \>120%) during the preceding trial.~* administration of ARBs or dihydropyridine CCBs (apart from trial medication). any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient age ≥ 5 years~2. Presence of P. knowlesi malaria, confirmed by positive blood smear with asexual forms of P. knowlesi.~3. Temperature \>38C on admission or fever during the preceding 48 hours~4. Enrolled within 18 hours of commencing antimalarial treatment~5. Written informed consent from patient or attending relative able to and willing to give informed consent. Consent form and information sheets will be translated into Malay and copies provided to the patient.~Exclusion Criteria:~1. Patient or relatives unable or unwilling to give informed consent~2. Contraindication or allergy to paracetamol or artesunate therapy~3. Known cirrhosis, or \>6 standard alcoholic drinks/day~4. Pregnancy

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paracetamol (Type: EXPERIMENTAL): \>50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.~\<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine.
- No Paracetamol (Type: NO_INTERVENTION): No Paracetamol plus IV artesunate or oral artemether/lumefantrine.~If temperature \>39.5°C, tepid sponging and mechanical antipyresis will be performed by research staff and/or relatives.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: \> or equal to 18 years and \< or equal to 85 years~* Documented ischemia with Rutherford classification 2, 3, or 4~* Target lesion in the SFA and/or PPA~* Angiographic evidence that target lesion consists of a single de novo or non-stented restenotic lesion or is a combination lesion that meets the following criteria:~  1. 70 - 99% occlusion by visual estimate with lesion length \> or equal to 4 cm and \< or equal to 18 cm~ 2. 100% occlusion by visual estimate with lesion length \< or equal to 10 cm~ 3. Combination lesions must have a total lesion length of \> or equal to 4 cm and \< or equal to 18 cm with an occluded segment that is \< or equal to 10 cm (by visual estimate)~* Target vessel diameter \> or equal to 4 mm and \< or equal to 7 mm~* Angiographic evidence of adequate distal run-off to the ankle~* Able to walk without assistive devices~Exclusion Criteria:~* Stroke or heart attack within 3 months prior to enrollment~* Enrolled in another investigational drug, device or biologic study~* Any surgical procedure or intervention performed within 30 days prior to or post index procedure~* SFA or PPA disease in the opposite leg that requires treatment at the index procedure~* Failure to successfully cross the target lesion~* Angiographic evidence of severe calcification~* Target lesion requires treatment with alternative therapies such as stenting, laser, atherectomy, cryoplasty, brachytherapy, re-entry devices)~* Known allergies or sensitivity to heparin, aspirin, other anticoagulant/antiplatelet therapies, paclitaxel or contrast media that cannot be adequately pre-treated prior to index procedure~* Chronic kidney disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Drug-Coated Balloon (DCB) (Type: EXPERIMENTAL): IN.PACT Admiral: Balloon Angioplasty
- Standard PTA (Type: ACTIVE_COMPARATOR): Standard Percutaneous Balloon Angioplasty (PTA) Balloon: Balloon Angioplasty

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Study of PTHrP and PTH to Treat Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 45 - 75 year old Caucasian, Hispanic or Asian women~* one year post-menopausal if older than 50 years~* three years post-menopausal if between the ages of 45 - 50 years~* body mass index less than or equal to 30~* T-scores on screening Dual X-Ray Absorbiometry (DXA) scan between - 2.0 to - 4.5 of lumbar spine or hip~* have at lease two spinal vertebrae evaluable by DXA analysis~Exclusion Criteria:~* bisphosphonate therapy within the last two years~* estrogen replacement hormones or SERMS within last one year~* no more than one week of PTHrP, PTH, or an analog of PTH within the last year~* an atraumatic bone fracture within the last 6 months~* significant or active diseases of any organ system~* history of malignancy~* anemia with a hematocrit less than 34%~* significant drug or alcohol abuse~* having received any investigational drug within the last 90 days~* taking any medication that may interfere with skeletal metabolism, such as phenobarbital, dilantin, glucocorticoids, and hydrochlorathiazide~* abnormal screening labs including serum Ca greater than 10.5 g/dl, 25 hydroxy vitamin D less than 20 ng/ml or PTH greater than 65 pg/ml~* African-Americans for this particular study - although future studies are planned

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- PTHrP 400 mcg/day (Type: EXPERIMENTAL): Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months.
- PTHrP 600 mcg/day (Type: EXPERIMENTAL): Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months.
- PTH 20 mcg/day (Type: ACTIVE_COMPARATOR): Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* be at least 18 years old~* be willing and able to avoid all disallowed medications and contact lenses~* must have a pregnancy test if of childbearing potential~* must be able to read an eye chart from 10 feet away~Exclusion Criteria:~* must not have any allergies to the study medications~* must not have any ocular or non ocular condition that investigator feels will interfere with study parameters~* must not have used immunotherapy in the last 2 years~* must not have used an investigational drug or device in the past 30 days or concurrently enrolled in another investigational trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bilastine Ophthalmic Solution 0.6% (Type: EXPERIMENTAL): Bilastine Ophthalmic Solution 0.6%~1 drop in each eye at 2 separate times during an 8 day period.
- Ketotifen Ophthalmic Solution 0.025% (Zaditen) (Type: ACTIVE_COMPARATOR): Ketotifen Ophthalmic Solution 0.025% (Zaditen)~1 drop in each eye at 2 separate times during an 8 day period.
- Vehicle of Bilastine Ophthalmic Solution (Type: PLACEBO_COMPARATOR): Vehicle of Bilastine Ophthalmic Solution~1 drop in each eye at 2 separate times during an 8 day period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, aged 18 or older (except in South Korea, aged 19 or older).~* Histologically confirmed marginal zone lymphoma, including extranodal, nodal, and splenic subtypes.~* Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ≥ 1 lesion that measures \> 1.5 cm in the longest transverse diameter and ≥ 1.0 cm in the longest perpendicular diameter.~* Participants with splenic MZL who do not meet the radiographically measurable disease criteria described herein are eligible for participation provided that bone marrow infiltration of MZL is histologically confirmed.~* Participants must be willing to undergo an incisional or excisional lymph node or tissue biopsy or provide a lymph node or tissue biopsy from the most recent available archival tissue.~* Eastern Cooperative Oncology Group performance status 0 to 2.~Exclusion Criteria:~* Evidence of diffuse large B-cell transformation.~* History of central nervous system lymphoma (either primary or metastatic) or leptomeningeal disease.~* Prior treatment with idelalisib, other selective PI3Kδ inhibitors, or a pan-PI3K inhibitor.~* Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of the first dose of study treatment.~* Active graft versus host disease.~* Subjects positive for hepatitis B surface antigen or hepatitis B core antibody will be eligible if they are negative for HBV-DNA. Subjects positive for anti-HCV antibody will be eligible if they are negative for HCV-RNA.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1- Closed to Further enrollment (Type: EXPERIMENTAL): Participants who have received prior ibrutinib.
- Cohort 2 (Type: EXPERIMENTAL): Participants who have not received a prior BTK inhibitor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18- 42 (upon starting COH);~* BMI \<30 kg/m2;~* \<3 prior ART cycles (IVF, ICSI and related procedures);~* Baseline (day 2-3 of cycling) FSH \<15 IU/L and E2 \<80 pg/mL;~* Normal uterine cavity as per recent hysterosalpingogram, sonohysterogram or hysteroscopic exam (i.e. no polyp or protruding sub-mucosal fibroid);~* At least 3 retrieved oocytes;~* Patient has given written informed consent.~Exclusion Criteria:~* Intramural uterine fibroids that distort the uterine cavity or polyps \>1 cm;~* Stage III or IV endometriosis (endometriomas);~* Hydrosalpinx;~* History of past poor response to COH resulting in canceling ART;~* Use of thawed/donated oocytes;~* Use of thawed/donated embryos;~* Patients affected by pathologies associated with any contraindication of being pregnant;~* Hypersensitivity to study medication;~* Uncontrolled adrenal or thyroid dysfunction;~* Undiagnosed vaginal bleeding;~* History of arterial disease;~* Patients with hepatic impairment;~* Neoplasias (current) or history of neoplasia that may be responsive to progesterone;~* High grade cervical dysplasia;~* Active thrombophlebitis or thromboembolic disorders, or a history of hormone-associated thrombophlebitis or thromboembolic disorders;~* History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages wherein pregnancy developed to a minimum of a gestational sac on TVUS;~* Participation in a concurrent clinical trial or another trial within the past 2 months;~* Use of concomitant medications that might interfere with the study evaluation;~* Pre-implantation genetic diagnosis/screening.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- Progesterone SC (Type: EXPERIMENTAL): None
- Progesterone Vaginal gel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete